Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
HPV
cervical screening
genotyping
methylation
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
20 Mar 2024
20 Mar 2024
Historique:
revised:
09
01
2024
received:
20
09
2023
accepted:
08
02
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
aheadofprint
Résumé
Methylation markers have shown potential for triaging high-risk HPV-positive (hrHPV+) women to identify those at increased risk of invasive cervical cancer (ICC). Our aim was to assess the performance of the S5 DNA methylation classifier for predicting incident high-grade cervical intraepithelial neoplasia (CIN) and ICC among hrHPV+ women in the ARTISTIC screening trial cohort. The S5 classifier, comprising target regions of tumour suppressor gene EPB41L3 and L1 and L2 regions of HPV16, HPV18, HPV31, and HPV33, was assayed by pyrosequencing in archived hrHPV+ liquid-based samples from 343 women with high-grade disease (139 CIN2, 186 CIN3, and 18 ICC) compared to 800 hrHPV+ controls. S5 DNA methylation correlated directly with increasing severity of disease and inversely with lead time to diagnosis. S5 could discriminate between hrHPV+ women who developed CIN3 or ICC and hrHPV+ controls (p <.0001) using samples taken on average 5 years before diagnosis. This relationship was independent of cytology at baseline. The S5 test showed much higher sensitivity than HPV16/18 genotyping for identifying prevalent CIN3 (93% vs. 61%, p = .01) but lower specificity (50% vs. 66%, p <.0001). The S5 classifier identified most women at high risk of developing precancer and missed very few prevalent advanced lesions thus appearing to be an objective test for triage of hrHPV+ women. The combination of methylation of host and HPV genes enables S5 to combine the predictive power of methylation with HPV genotyping to identify hrHPV-positive women who are at highest risk of developing CIN3 and ICC in the future.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK
ID : C8162/A4609
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8162/A10406
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C569/A10404
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C236/A
Pays : United Kingdom
Informations de copyright
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Bouvard V, Wentzensen N, Mackie A, et al. The IARC perspective on cervical cancer screening. N Engl J Med. 2021;385(20):1908‐1918.
Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV‐based screening for prevention of invasive cervical cancer: follow‐up of four European randomised controlled trials. Lancet. 2014;383(9916):524‐532.
Tota JE, Bentley J, Blake J, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev Med. 2017;98:5‐14.
Cuschieri K, Ronco G, Lorincz A, et al. Eurogin roadmap 2017: triage strategies for the management of HPV‐positive women in cervical screening programs. Int J Cancer. 2018;143(4):735‐745.
Kitchener H. Report to the National Screening Committee. 2015 Available from: https://view-health-screening-recommendations.service.gov.uk/document/320/download
Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;6(364):l240.
Loopik DL, Koenjer LM, Siebers AG, Melchers WJG, Bekkers RLM. Benefit and burden in the Dutch cytology‐based vs high‐risk human papillomavirus‐based cervical cancer screening program. Am J Obstet Gynecol. 2020;224:200.e1‐9.
Serrano B, Ibanez R, Robles C, Peremiquel‐Trillas P, de Sanjose S, Bruni L. Worldwide use of HPV self‐sampling for cervical cancer screening. Prev Med. 2022;154:106900.
Rebolj M, Sargent A, Njor SH, Cuschieri K. Widening the offer of human papillomavirus self‐sampling to all women eligible for cervical screening: make haste slowly. Int J Cancer. 2023;153(1):8‐19.
Australian_Government. National Cervical Screening Policy [01/06/2020]. Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/national‐cervical‐screening‐policy
Kelly H, Benavente Y, Pavon MA, de Sanjose S, Mayaud P, Lorincz AT. Performance of DNA methylation assays for detection of high‐grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta‐analysis. Br J Cancer. 2019;121(11):954‐965.
Barrett JE, Sundstrom K, Jones A, et al. The WID‐CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. Genome Med. 2022;14(1):116.
Vink FJ, Meijer C, Clifford GM, et al. FAM19A4/miR124‐2 methylation in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Int J Cancer. 2020;147(4):1215‐1221.
Lehtinen M, Pimenoff VN, Nedjai B, et al. Assessing the risk of cervical neoplasia in the post‐HPV vaccination era. Int J Cancer. 2023;152(6):1060‐1068.
Nedjai B, Reuter C, Ahmad A, et al. Molecular progression to cervical precancer, epigenetic switch or sequential model? Int J Cancer. 2018;143(7):1720‐1730.
Louvanto K, Aro K, Nedjai B, et al. Methylation in predicting progression of untreated high‐grade cervical intraepithelial neoplasia. Clin Infect Dis. 2020;70(12):2582‐2590.
Clarke MA, Wentzensen N, Mirabello L, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2125‐2137.
Hernandez‐Lopez R, Lorincz AT, Torres‐Ibarra L, et al. Methylation estimates the risk of precancer in HPV‐infected women with discrepant results between cytology and HPV16/18 genotyping. Clin Epigenetics. 2019;11(1):140.
Ramirez AT, Sanchez GI, Nedjai B, et al. Effective methylation triage of HPV positive women with abnormal cytology in a middle‐income country. Int J Cancer. 2021;148(6):1383‐1393.
Banila C, Lorincz AT, Scibior‐Bentkowska D, et al. Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: a worldwide study. Int J Cancer. 2022;150(2):290‐302.
Dick S, Vink FJ, Heideman DAM, Lissenberg‐Witte BI, Meijer C, Berkhof J. Risk‐stratification of HPV‐positive women with low‐grade cytology by FAM19A4/miR124‐2 methylation and HPV genotyping. Br J Cancer. 2022;126(2):259‐264.
Zeng R, Liu Y, Jiang ZJ, et al. EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int J Oncol. 2018;52(5):1443‐1454.
Brentnall AR, Vasiljevic N, Scibior‐Bentkowska D, et al. HPV33 DNA methylation measurement improves cervical pre‐cancer risk estimation of an HPV16, HPV18, HPV31 and \textitEPB41L3 methylation classifier. Cancer Biomark. 2015;15(5):669‐675.
Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1‐150. iii‐iv.
Lorincz AT, Brentnall AR, Vasiljevic N, et al. HPV16 L1 and L2 DNA methylation predicts high‐grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer. 2013;133(3):637‐644.
Lorincz AT, Brentnall AR, Scibior‐Bentkowska D, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138(11):2745‐2751.
Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in cervical screening: long‐term follow‐up of ARTISTIC RCT. Health Technol Assess. 2019;23(28):1‐44.
Cuzick J. A Wilcoxon‐type test for trend. Stat Med. 1985;4(1):87‐90.
Tukey JW. Exploratory Data Analysis. Addison‐Wesley; 1977.
Adcock R, Nedjai B, Lorincz AT, et al. DNA methylation testing with S5 for triage of high‐risk HPV positive women. Int J Cancer. 2022;151(7):993‐1004.
Cook DA, Krajden M, Brentnall AR, et al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int J Cancer. 2019;144(10):2587‐2595.
Dick S, Kremer WW, de Strooper LMA, et al. Long‐term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124‐2 methylation analysis. Gynecol Oncol. 2019;154(2):368‐373.
Zhang L, Zhao X, Hu S, et al. Triage performance and predictive value of the human gene methylation panel among women positive on self‐collected HPV test: results from a prospective cohort study. Int J Cancer. 2022;151(6):878‐887.
de Strooper LMA, Berkhof J, Steenbergen RDM, et al. Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: a post hoc analysis in the POBASCAM trial with 14 year follow‐up. Int J Cancer. 2018;143(6):1541‐1548.
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Lancet Oncol. 2010;11(11):1048‐1056.
Cuzick J, Adcock R, Wheeler CM. HPV genotype‐specific risk for cervical cancer. wwwHPVWorldcom. 2021;181.
Gilham C, Sargent A, Peto J. Triaging women with human papillomavirus infection and normal cytology or low‐grade dyskaryosis: evidence from 10‐year follow up of the ARTISTIC trial cohort. BJOG. 2020;127(1):58‐68.
Pimenoff VN, Gray P, Louvanto K, et al. Ecological diversity profiles of non‐vaccine‐targeted HPVs after gender‐based community vaccination efforts. Cell Host Microbe. 2023;31(11):1921‐1929.e3.